Get the Stockscreener App
4.61
7.80%
-0.39
After Hours:
4.64
0.03
+0.65%
Precision Biosciences Inc stock is traded at $4.61, with a volume of 368.27K.
It is down -7.80% in the last 24 hours and up +5.25% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$5.00
Open:
$4.85
24h Volume:
368.27K
Relative Volume:
1.52
Market Cap:
$54.34M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-6.9848
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
-9.07%
1M Performance:
+5.25%
6M Performance:
-8.89%
1Y Performance:
-56.05%
1-Day Range:
$4.50
$4.9664
1-Week Range:
$4.50
$5.14
52-Week Range:
$3.61
$10.68
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.61 | 59.05M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences presents data from hepatitis B gene editing trial By Investing.com - Investing.com Australia
Can Precision BioSciences Inc. hit a new high this monthGlobal Markets & Free High Return Stock Watch Alerts - Newser
Is Precision BioSciences Inc. stock poised for growthWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial - Contract Pharma
Will Precision BioSciences Inc. bounce back from current supportTreasury Yields & AI Powered Market Entry Strategies - Newser
Custom strategy builders for tracking Precision BioSciences Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th Inte - PharmiWeb.com
Precision BioSciences presents phase 1 PBGENE-HBV trial data at HBV Cure Symposium; targets chronic hepatitis B - MarketScreener
Precision BioSciences presents data from hepatitis B gene editing trial - Investing.com
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium - Yahoo Finance
Statistical indicators supporting Precision BioSciences Inc.’s strengthJuly 2025 Chart Watch & Advanced Technical Analysis Signals - Newser
Risk adjusted return profile for Precision BioSciences Inc. analyzedJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - Newser
Will Precision BioSciences Inc. price bounce be sustainableTrade Entry Report & Reliable Price Breakout Signals - Newser
Top chart patterns to watch in Precision BioSciences Inc.July 2025 Highlights & Reliable Breakout Forecasts - Newser
Will Precision BioSciences Inc. continue its uptrendEarnings Overview Report & Daily Profit Maximizing Trade Tips - Newser
What MACD and RSI say about Precision BioSciences Inc.2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Comparing Precision BioSciences Inc. in custom built stock radarsMarket Growth Review & Free AI Powered Buy and Sell Recommendations - Newser
Can Precision BioSciences Inc. rally from current levelsIndex Update & Reliable Price Breakout Alerts - Newser
Precision BioSciences Inc. stock daily chart insightsTrade Exit Summary & Low Risk High Win Rate Picks - Newser
What recovery options are there for Precision BioSciences Inc.Weekly Risk Report & AI Powered Trade Plan Recommendations - Newser
Tools to assess Precision BioSciences Inc.’s risk profileEarnings Trend Report & Daily Technical Forecast Reports - Newser
Detecting support and resistance levels for Precision BioSciences Inc.Dividend Hike & Smart Allocation Stock Reports - Newser
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status - BioSpace
Precision BioSciences secures US patent for hepatitis B gene editing therapy - Investing.com
Precision BioSciences announces U.S. patent covering PBGENE-HBV for Chronic Hepatitis B and updates program status - MarketScreener
Custom watchlist performance reports with Precision BioSciences Inc.IPO Watch & Risk Controlled Swing Alerts - Newser
Will Precision BioSciences Inc. announce a stock split2025 Performance Recap & Daily Entry Point Trade Alerts - خودرو بانک
Real time alert setup for Precision BioSciences Inc. performance2025 Market Overview & Fast Moving Stock Watchlists - Newser
What’s the beta of Precision BioSciences Inc. stock2025 Key Lessons & Daily Price Action Insights - خودرو بانک
Using flow based indicators on Precision BioSciences Inc.2025 Big Picture & High Win Rate Trade Alerts - Newser
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Strategies to average down on Precision BioSciences Inc.July 2025 PreEarnings & AI Enhanced Trading Alerts - Newser
How to manage a losing position in Precision BioSciences Inc.July 2025 Selloffs & AI Driven Price Predictions - Newser
Published on: 2025-09-04 07:13:23 - Newser
Signal strength of Precision BioSciences Inc. stock in tech scannersMarket Volume Report & Growth Focused Investment Plans - Newser
Can Precision BioSciences Inc. recover in the next quarterJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - Newser
Precision BioSciences Inc.’s volatility index tracking explainedShort Setup & Real-Time Volume Analysis Alerts - Newser
How to use Fibonacci retracement on Precision BioSciences Inc.Jobs Report & Growth Oriented Trading Recommendations - Newser
Visual analytics tools that track Precision BioSciences Inc. performanceJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - Newser
Precision BioSciences Updates Executive Employment Agreements - The Globe and Mail
Published on: 2025-09-03 01:30:24 - Newser
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):